Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | TPSAB1 | Q15661 | 6/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.51 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.49 |
| ▸ | KLK1 | P06870 | 3/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylamine SCHEMBL910097 | 0.92 | CYP1A2 (1.00) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL11533429 | 0.89 | CYP2C9 (0.65) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL258716 | 0.84 | CYP2C9 (0.62) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL1500540 | 0.84 | CYP1A2 (0.79) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL20705214 | 0.83 | CYP2C19 (0.61) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL626651 | 0.83 | TPSAB1 (0.70) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL7441659 | 0.83 | CYP2C9 (0.60) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL8602062 | 0.82 | CYP2C9 (0.59) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL5879548 | 0.82 | CYP1A2 (0.76) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR | |
| SCHEMBL23571643 | 0.81 | TPSAB1 (0.81) | CYP2C9CYP2C19CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240174772-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240174675-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-30 | — | — | US | disclosed |
| US-11981670-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2024-04-18 | — | — | US | disclosed |
| US-11932708-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2024020684-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026064-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-1482941-A4 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1577292-A1 | Phenylaminoethanol derivatives as beta2 receptor agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1482941-A1 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | Myriad Pharmaceuticals, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | MYRIAD PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | US | disclosed |
| WO-2003068234-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068237-A1 | BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| EP-1171435-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061551-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
| US-5830920-A | PREVENTION GROWTH OF SMOOTH MUSCLE CELLS | HOFFMANN-LA ROCHE INC. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0000815-B1 | PROCESS FOR PREPARING N-ARYL OR N-ARALKYL SUBSTITUTED URETHANES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981670-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | TLR7, TLR8, TLR3 | CYP2C9 3342/4885CYP2C19 3488/4885CYP1A2 2363/4885 |
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | TPSAB1, TPSB2, TPSD1 | CYP2C9 2968/4885CYP2C19 2992/4885CYP1A2 2611/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | CYP2C9 4182/4885CYP2C19 4310/4885CYP1A2 4292/4885 |
| US-20240174675-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, DPP3 | CYP2C9 4880/4885CYP2C19 4881/4885CYP1A2 4791/4885 |
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | DHFR, RARS2, DPYD | CYP2C9 538/4885CYP2C19 311/4885CYP1A2 1687/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | CYP2C9 4575/4885CYP2C19 3035/4885CYP1A2 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.